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Objective: Despite available medical therapies, patients with peripheral arterial disease (PAD) remain at high risk for
cardiovascular events. The n-3 polyunsaturated fatty acids (PUFA), derived from marine sources, have been shown to
improve cardiovascular mortality. The Omega-3 Index (O3I), a proportion of the n-3 PUFA eicosapentaenoic acid and
docosahexaenoic acid in the red blood cell membrane, correlates with cardiovascular risk. Previous investigations have
found that n-3 PUFA supplementation, ﬁsh consumption, older age, and smoking history affect the O3I in different
patient populations, although similar correlations have never been explored in PAD. We hypothesized that in our PAD
cohort, blood content of omega-3 fatty acids would directly and positively correlate with a history of ﬁsh oil supple-
mentation and older age and inversely correlate with a smoking history and obesity.
Methods: This cross-sectional study included 111 patients who had an ankle-brachial index of <0.9 associated with
claudication symptoms. We used linear regression to determine the association between clinical factors and the O3I.
Results: The mean age of the cohort was 69 6 8 years; 37% had diabetes mellitus (hemoglobin A1c, 7% 6 1%), and 94%
reported current smoking or a history of smoking. The mean O3I was 5% 6 2%. In multivariate linear regression analysis,
the O3I was associated with older age, increasing body mass index, and a history of smoking and ﬁsh oil intake.
Conclusions: This is the ﬁrst report of the relation between blood content of omega-3 fatty acids and clinical factors in a
PAD population. In patients with PAD, older age, elevated body mass index, and prior ﬁsh oil supplementation predicted
a higher O3I. A history of smoking correlated with a lower O3I. These results demonstrate that the O3I is a reliable
measure of dietary n-3 PUFA intake and that clinical factors related to the O3I in PAD are similar to those observed in
other populations. (J Vasc Surg 2014;60:1325-31.)In a primary care setting, nearly one third of patients
aged 70 years and older will suffer from peripheral arterial
disease (PAD),1 which signiﬁcantly affects their quality of
life and longevity. Despite the available medical therapies,
patients with PAD continue to have a higher risk of cardio-
vascular events compared with patients with coronary artery
disease (CAD).2 In addition to traditional risk factors, such as
diabetes mellitus, smoking, hyperlipidemia, and hyperten-
sion, a growing body of evidence indicates that inadequate
nutrient intake and excessive calorie intake contribute to
the development of PAD among other cardiovascular dis-
eases.3-6 Lower blood levels of omega-3 polyunsaturatedthe Department of Surgery,a Departments of Medicine and of
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The Omega-3 Index (O3I)dwhich is a measure of
red blood cell (RBC) content of the two major long-
chain n-3 PUFA, eicosapentaenoic acid (EPA) and doco-
sahexaenoic acid (DHA),8 expressed as a percentage of
total RBC fatty acidsdhas become a validated marker
of tissue n-3 PUFA content and an independent, graded
risk factor for death from CAD.9 We previously demon-
strated that the O3I was inversely associated with inﬂam-
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monolayer in vitro.11
Prior studies that evaluated clinical determinants of the
O3I in patients at risk for CAD found that a history of n-3
PUFA supplementation had the strongest positive predic-
tive value, followed by non-fried ﬁsh consumption and
older age; smoking history had a strong negative predictive
value.12,13 This study aimed to determine the clinical,
anthropometric, and lifestyle factors associated with the
O3I in patients with PAD because this patient population
is at greater cardiovascular risk than are patients with CAD
and the general population. A better understanding of
these associations could help guide future therapeutic in-
terventions, such as personalized dosing recommendations,
in an effort to improve PAD patients’ vascular function and
prognosis. On the basis of the associations observed by
previous investigators, we hypothesized that in our PAD
cohort, blood content of omega-3 fatty acids would
directly and positively correlate with a history of ﬁsh oil
supplementation and older age and inversely correlate
with a smoking history and obesity.
METHODS
Study population and protocol
This study used baseline data from a prospective trial
investigating the effects of n-3 PUFA supplementation
on inﬂammatory markers and vascular function in PAD pa-
tients.10 The investigator-initiated protocol was approved
by the Committee on Human Research at the University
of California, San Francisco, and all patients provided
informed consent. Patients referred to the outpatient
vascular surgery clinic of the San Francisco Veterans
Affairs Medical Center (SF VAMC) for evaluation of
PAD were screened for the study.
PAD diagnosis was based on current guidelines of an
ankle-brachial index (ABI) <0.9 on the affected limb at
presentation with the presence of claudication.14 We
excluded patients with incompressible arteries or an ABI
>1.4. None of the participants had pain at rest or tissue
loss. Claudication was diagnosed on the basis of fatigue,
discomfort, or pain that occurs in speciﬁc limb muscle
groups during effort due to exercise-induced ischemia.15
The study exclusion criteria included signiﬁcant renal
(creatinine level #2 mg/dL), hepatic (active or acute
hepatic disease, although nonactive chronic hepatitis C
was not considered an exclusion criterion), or inﬂammatory
disease (eg, Crohn disease, ulcerative colitis, primary biliary
cirrhosis, sclerosing cholangitis); concurrent severe infec-
tions; acute illness or other major surgery within 30 days
of evaluation; and ingestion of immunosuppressive medica-
tions. Those meeting inclusion criteria were invited to
enter the research study, at which time informed consent
was obtained by study staff in accordance with require-
ments of the Committee for Human Research. Data on
demographics (age, race, and gender), anthropometrics
(hip and waist circumference, body mass index [BMI]),
lifestyle (prior supplement use and cigarette smoking),cardiovascular disease history (eg, CAD and previous car-
diovascular procedures), cardiovascular disease risk factors
(hypertension, diabetes, hypercholesterolemia, and ciga-
rette smoking), medications, and pertinent vascular exami-
nation ﬁndings were recorded. Circulating biomarkers
were also studied, including the O3I and the inﬂammatory
markers C-reactive protein (CRP), interleukin 6 (IL-6),
and tumor necrosis factor a (TNF-a), and lipids (low-
density lipoprotein cholesterol, triglycerides, high-density
lipoprotein cholesterol), blood pressure, and bilateral ABI
were measured. A validated food frequency questionnaire
was also administered to estimate dietary intake.16
Measurements
RBC fatty acids. To measure the O3I, whole venous
blood was collected in a fasting state in an ethylenediamine-
tetraacetic acid (EDTA) tube and centrifuged at 2800 rpm
for 10 minutes at 4C within 30 minutes of collection. After
removal of the plasma and buffy coat, packed RBCs were
stored at 80C until assayed as previously described.17
Among the fatty acids quantiﬁed were n-3 and n-6 fatty
acids, arachidonic acid, EPA, DHA, O3I, saturated fatty
acids, trans-fatty acids, and monounsaturated fatty acids.
Fatty acid methyl esters are generated from RBCs by acid
transesteriﬁcation with boron triﬂuoride and analyzed by
capillary gas chromatography with a GC2010 Gas Chro-
matograph (ShimadzuCorp, Columbia,Md) equippedwith
a SP2560, 100-m column (Supelco, Bellefonte, PA). Fatty
acids were identiﬁed by comparison with a standard mixture
of fatty acids characteristic of erythrocytes and reported as a
percentage of total identiﬁed fatty acids after response factor
correction. C18 trans-fatty acids were deﬁned as the sum of
the trans-isomers of oleic acid (C18:1) and linoleic acid
(C18:2n-6). The typical coefﬁcient of variation with this
procedure is 3% for the O3I (EPA and DHA) and 7% for
trans-fatty acids.
Inﬂammatory markers. Inﬂammatory markers stud-
ied included CRP, IL-6, and TNF-a. These biomarkers
were chosen on the basis of their association with disease
severity in PAD.18-21 Whole venous blood was collected in
a fasting state in an SSTP tube, allowed to clot for a min-
imum of 30 minutes at room temperature, and centrifuged
at 2800 rpm for 10 minutes at 4C. Serum was stored
at 80C until assayed for IL-6 and TNF-a per standard
kit protocol (R&D Systems Inc, Minneapolis, Minn). The
typical coefﬁcients of variation for IL-6 and TNF-a are
7.4% and 5.4%, respectively. The lower limits of detection
are 0.04 pg/mL and 0.11 pg/mL, respectively. Plasma
obtained from the EDTA tubes described before was
assayed for CRP on the same day as collection by the SF
VAMC laboratory per standard methodology (Beckman
Coulter Analyzer, Miami, Fla). The coefﬁcient of variation
for CRP with this procedure is 5.1%.
ABI. The ABI was measured by use of current guide-
lines and standards.14 ABI measurements were collected by
trained vascular clinical staff of the Vascular Integrated
Physiology and Experimental Therapeutics (VIPERx Lab-
oratory; see www.viperxlab.org for more details), which is
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blood pressures of the brachial, posterior tibial, and dorsalis
pedis arteries were measured bilaterally. For each lower
extremity, the highest systolic pressure of the two pedal
pulses was divided by the highest systolic pressure of the
two brachial arteries.
Renal, lipid, and metabolic measurements. EDTA
blood samples were collected in a fasting state for measure-
ment of creatinine, estimated glomerular ﬁltration rate,
albumin, total cholesterol, triglycerides, low-density lipo-
protein, high-density lipoprotein, and hemoglobin A1c
if patients were diabetic. Plasma was assayed for these
analytes on the same day as collection by the SF VAMC
laboratory per standard methodology (Beckman Coulter
Analyzer). Serum was isolated at the same time points
as described before and assayed for homocysteine on the
same day as collection by the SF VAMC laboratory per
standard methodology (Architect i1000 Analyzer; Abbott
Diagnostics, Lake Forest, Ill).
Statistical analysis
For descriptive purposes, we categorized participants
by tertiles based on the O3I. Differences in baseline char-
acteristics between these groups were compared by analysis
of variance for continuous variables, the c2 test for categor-
ical dichotomous variables, and the Kruskal-Wallis test for
categorical variables with multiple designations (eg, Ruth-
erford classiﬁcation). Because inﬂammatory markers and
homocysteine had a skewed distribution, they were log-
transformed for subsequent statistical analyses. For regres-
sion modeling, the O3I was used as a continuous variable.
We used multivariable linear regression models to estimate
the relationship between the O3I and various clinical, life-
style, and anthropometric factors. We employed a stepwise
process to construct the multivariable model, incorporating
the independent predictor variables from univariate anal-
ysis as well as high-density lipoprotein cholesterol, low-
density lipoprotein cholesterol, and triglyceride levels, fac-
tors found to signiﬁcantly correlate with the O3I in a pre-
vious study by Block et al.12 Covariates associated with the
O3I at P < .05 were retained. Statistical analyses were per-
formedwith Stata/SE12 (StataCorp, College Station, Tex).RESULTS
A total of 111 patients with PAD were recruited for the
study, and all reported lifestyle-limiting lower extremity
claudication. The mean age of the cohort was 696 8 years;
40% had CAD, 37% had diabetes mellitus (hemoglobin
A1c, 7% 6 1%), and 94% reported current smoking or a
history of smoking. The mean O3I was 5.2% 6 1.8%. The
demographics, medications, and lifestyle characteristics of
the population and laboratory studies are summarized in
Table I by O3I tertiles. The patients with a higher O3I
were more likely to be older and to lack a smoking history.
There was a trend for subjects with increasing O3I levels to
have a higher BMI. A greater proportion of patients with a
higher O3I also reported supplementation with n-3 PUFA.The constituent fatty acids that make up the RBC
membrane also differed across O3I tertiles (Table II).
Patients with a higher O3I were more likely to have higher
levels of n-3 PUFA and in particular EPA and DHA.
A lower O3I was associated with a greater proportion of
n-6 PUFA. Levels of saturated fatty acids, trans-fatty acids,
and monounsaturated fatty acids were relatively equal
across the three tertiles.
The results from univariate and subsequent multivariable
regression analyses are detailed in Table III. In univariate
analyses, older age (P ¼ .003), increasing BMI (P ¼ .05),
a diagnosis of hypertension (P ¼ .03), and a history of n-3
PUFA supplementation (P< .001)were found to positively
correlate with the O3I. A history of smoking (P ¼ .003)
correlated with a lower O3I. In a multivariable model, an
independent association remained with age by each succes-
sive decade (P ¼ .001), BMI increasing by intervals of
5 (P ¼ .001), a history of smoking or current smoking
(P ¼ .03), and supplementation with n-3 PUFA (P ¼ .001).
To further explore the association with higher BMI and the
O3I, we recategorized BMI into two groups: BMI >30
(n ¼ 37 of 111) and BMI <30 (n ¼ 74). In running of a
univariate analysis to include only the 37 patients with a
BMI >30, there was no longer a signiﬁcant correlation with
the O3I. We further recategorized the data into BMI >35
(n¼12) andBMI<35(n¼99) and similarly observedno sig-
niﬁcant association with the O3I.
DISCUSSION
In a prospective cohort study of patients presenting for
evaluation of PAD in an outpatient vascular surgery clinic,
we found that older age, increasing BMI, and prior ﬁsh oil
supplementation predicted a higher O3I. A history of
smoking correlated with a lower O3I. These ﬁndings
conﬁrm associations observed in non-PAD populations.
Our observations suggest that targeting dietary ﬁsh con-
sumption and ﬁsh oil supplementation as well as tobacco
use with therapeutic interventions has potential to reduce
cardiovascular risk among PAD patients.
A decade ago, Harris and von Schacky22 proposed the
O3I as a biomarker of n-3 PUFA status on the basis that
the proportional EPA and DHA content in RBC mem-
branes provides a good estimation of n-3 PUFA intake.
Other studies demonstrated the utility of measuring blood
levels of long-chain PUFA for the purpose of cardiovascular
disease risk stratiﬁcation.23-25 A lower O3I has been shown
to be predictive of acute coronary syndrome,12,25 primary
cardiac arrest,23 and sudden cardiac death.24 On the basis
of these associations, Harris et al proposed graded O3I
risk zones for CAD, deﬁned as high risk, intermediate
risk, and low risk and corresponding to <4%, 4% to 8%,
and >8%, respectively. Compared with patients with
CAD, those with PAD have a more pronounced inﬂamma-
tory phenotype and are at increased risk for cardiovascular
events. PAD patients also have signiﬁcantly elevated risks of
limb amputation and premature mortality compared with
the general population.1,26 To our knowledge, a character-
ization of O3I levels among patients with PAD has not yet
Table I. Baseline characteristics of the population categorized by Omega-3 Index (O3I) tertiles
Descriptive characteristics
All patients
(N ¼ 111)
O3I tertile I
(2.79-4.10) (n ¼ 37)
O3I tertile II
(4.11-5.04) (n ¼ 37)
O3I tertile III
(5.06-12.33) (n ¼ 37) P valuea
Age, years 69 6 8 66 6 7 69 6 8 71 6 7 .02
Male sex 108 (97) 36 (97) 36 (97) 36 (97) 1.0
White race 84 (76) 29 (78) 27 (73) 28 (76) .3
BMI, kg/m2 28 6 5 27 6 5 28 6 4 29 6 6 .08
Waist-to-hip ratio 1.0 6 0.1 1.0 6 0.1 1.0 6 0.1 1.0 6 0.1 .3
Rutherford category .4
Mild claudication 33 (30) 12 (32) 7 (19) 14 (38)
Moderate claudication 32 (29) 12 (32) 10 (27) 10 (27)
Severe claudication 44 (40) 12 (32) 20 (54) 12 (32)
Blood pressure, mm Hg
Systolic 137 6 18 138 6 18 134 6 16 139 6 20 .5
Diastolic 76 6 10 76 6 11 75 6 9 76 6 8 .9
ABI 0.7 6 0.1 0.7 6 0.2 0.7 6 0.1 0.7 6 0.1 .6
Comorbidities
Hypertension 102 (92) 32 (86) 33 (89) 37 (100) .08
Hyperlipidemia 96 (86) 30 (81) 32 (86) 34 (92) .4
History of CAD 44 (40) 13 (35) 14 (38) 17 (46) .6
Diabetes mellitus 41 (37) 11 (30) 13 (35) 17 (46) .3
Medications or supplements
Aspirin 79 (71) 27 (73) 23 (62) 29 (78) .3
ACE inhibitor 51 (46) 14 (38) 19 (51) 18 (49) .5
b-Blocker 62 (56) 22 (59) 20 (54) 20 (54) .9
Statin 92 (83) 30 (81) 29 (78) 33 (89) .4
Insulin use, if diabetic 15 (14) 3 (8) 6 (16) 6 (16) .7
History of ﬁsh oil intake 38 (35) 10 (28) 8 (22) 20 (56) .005
PAD risk factors
History of smoking 104 (94) 37 (100) 36 (97) 31 (84) .009
Pack-years, if applicable 47 6 35 52 6 38 51 6 38 37 6 25 .2
Cholesterol, mg/dL
Total 160 6 41 168 6 41 161 6 40 152 6 42 .2
Low-density lipoprotein 87 6 36 92 6 35 87 6 34 81 6 39 .4
High-density lipoprotein 45 6 14 43 6 12 45 6 16 46 6 13 .6
Triglycerides, mg/dL 149 6 91 173 6 108 147 6 88 126 6 68 .1
Laboratory studies
O3I 5.0 6 1.8 3.6 6 0.3 4.6 6 0.3 6.8 6 1.9 <.001
logCRP, mg/dL 1.0 6 1.0 1 6 1 1 6 1 0.7 6 1 .2
logHomocysteine, mmol/L 2.6 6 0.3 3 6 0.4 3 6 0.3 3 6 0.2 .008
eGFR, mL/min/1.73 m2 73 6 23 80 6 24 67 6 22 75 6 21 .07
Creatinine, mg/dL 1.2 6 0.7 1 6 0.4 1 6 0.4 1 6 1 .5
Albumin, g/dL 4.0 6 0.3 4 6 0.3 4 6 0.4 4 6 0.3 .2
ABI, Ankle-brachial index; ACE, angiotensin-converting enzyme; CAD, coronary artery disease; CRP, C-reactive protein; eGFR, estimated glomerular
ﬁltration rate; PAD, peripheral arterial disease.
Mean 6 standard deviation presented for continuous variables; number of patients with relative percentage of cohort presented for categorical variables.
aP value calculated from analysis of variance for continuous variables or either the Kruskal-Wallis test or c2 test for categorical variables.
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tive levels of n-3 PUFA with the O3I in a PAD cohort
and to determine associated clinical risk factors.
Prior reports have attempted to deﬁne determinants of
the O3I in at-risk populations. The ﬁrst was a cross-
sectional analysis of outpatients.12 The most signiﬁcant
predictors of a favorable O3I were EPA and DHA supple-
ment use and frequency of non-fried ﬁsh consumption.
Older age and a history of dyslipidemia were also associated
with a higher O3I, whereas factors that negatively associ-
ated with the O3I were smoking history and triglyceride
level. Another cross-sectional study by Sala-Vila et al13
included subjects from Spain with several risk factors but
without diagnosed cardiovascular disease or PAD. The
authors noted that rates of cardiac death among the
Mediterranean population in general are relatively lowdespite a high prevalence of risk factors. They hypothesized
that the regional diet may be protective by increased intake
of seafood, which is a rich source of EPA and DHA.
Consistent with this hypothesis, their study cohort had an
average O3I of 7.1%, which is higher than the reported
average of approximately 5% in other Western popula-
tions.12 After adjustment for demographic and lifestyle fac-
tors and energy expenditure, they also found that EPA and
DHA intake was the principal O3I determinant.
The strongest predictor of a higher O3I in the current
study was a history of supplementation with n-3 PUFA.
This ﬁnding is consistent with the results of Block et al
and Sala-Vila et al and provides further justiﬁcation that
the O3I is a good reﬂection of dietary intake of n-3
PUFA. Furthermore, in a recent dose-response random-
ized controlled trial that investigated supplementation
Table III. Predictors of the Omega-3 Index (O3I) in univariate and multivariate linear regression analysis (included if
P # .05)
Univariate analysis (n ¼ 111) Multivariate analysis (n ¼ 84)
Independent variable Coefﬁcient
95% Conﬁdence interval
P value Coefﬁcient
95% Conﬁdence interval
P valueLower limit Upper limit Lower limit Upper limit
Age, by decade 0.6 0.2 1.0 .003 0.8 0.3 1.2 .001
History of smoking 2.0 3.3 0.7 .003 1.5 2.7 0.2 .03
BMI, by increments of 5 0.3 0.01 0.6 .05 0.5 0.2 0.8 .001
Hypertension 1.3 0.1 2.5 .03 NS NS NS NS
History of n-3 supplementation 3.2 1.5 4.8 <.001 2.6 1.1 4.1 .001
BMI, Body mass index; NS, not signiﬁcant.
Table II. Constituent fatty acids of the red blood cell (RBC) membrane by Omega-3 Index (O3I) tertiles
Fatty acid, % cell membrane
All patients
(N ¼ 111)
O3I tertile I
(n ¼ 37)
O3I tertile II
(n ¼ 37)
O3I tertile III
(n ¼ 37) P valuea
u-3 Fatty acids, total 8 6 2 6 6 0.5 7 6 1 10 6 2 <.001
a-Linolenic C18:2n3 0.1 6 0.07 0.1 6 0.04 0.1 6 0.05 0.1 6 0.1 .3
Eicosapentaenoic C20:5n3 0.6 6 0.5 0.4 6 0.1 0.5 6 0.2 1 6 1 <.001
Docosapentaenoic-n3 C22:5n3 3 6 1 3 6 0.4 3 6 0.4 3 6 0.7 <.001
Docosahexaenoic C22:6n3 4 6 1 3 6 0.4 4 6 0.3 6 6 1 <.001
u-6 Fatty acids, total 35 6 3 37 6 2 36 6 1 33 6 3 <.001
Linoleic C18:2n6 11 6 2 11 6 2 11 6 1 10 6 2 .07
g-Linolenic C18:3n6 0.1 6 0.03 0.1 6 0.03 0.1 6 0.04 0.1 6 0.02 .01
Eicosadienoic C20:3n6 0.3 6 0.1 0.3 6 0.1 0.3 6 0.1 0.3 6 0.1 .4
Dihomo-g-linolenic C20:3n6 2 6 0.4 2 6 0.4 2 6 0.4 2 6 0.5 .9
Arachidonic C20:4n6 17 6 2 18 6 1 18 6 1 16 6 2 .01
Docosatetraenoic C22:4n6 5 6 1 5 6 1 5 6 1 4 6 1 <.001
Docosapentaenoic C22:5n6 1 6 0.3 1 6 0.2 1 6 0.2 1 6 0.3 .003
Saturated fat, total 41 6 1 41 6 1 41 6 1 41 6 1 1
Mysteric C14:0 0.3 6 0.1 0.3 6 0.1 0.3 6 0.1 0.3 6 0.1 .8
Palmitic C16:0 22 6 1 22 6 1 22 6 1 22 6 1 .9
Stearic C18:0 18 6 1 18 6 1 18 6 1 18 6 1 .7
Arachidic C20:0 0.1 6 0.03 0.1 6 0.04 0.1 6 0.03 0.1 6 0.03 .2
Behenic C22:0 0.1 6 0.1 0.1 6 0.1 0.1 6 0.1 0.2 6 0.1 .4
Lignoceric C24:0 0.3 6 0.2 0.3 6 0.2 0.3 6 0.1 0.4 6 0.2 .1
Trans fat, total 1 6 0.4 1 6 1 1 6 0.3 1 6 0.3 .01
Palmitelaidic C16:1n7t 0.1 6 0.04 0.1 6 0.04 0.1 6 0.04 0.1 6 0.04 .8
Elaidic C18:1t 1 6 0.4 1 6 0.5 1 6 0.3 1 6 0.2 .01
Linoelaidic C18:2n6t 0.3 6 0.1 0.3 6 0.1 0.3 6 0.1 0.3 6 0.1 .2
Monounsaturated fat, total 15 6 1 15 6 1 14 6 1 15 6 1 .04
Palmitoleic C16:1n7 0.3 6 0.2 0.3 6 0.1 0.3 6 0.1 0.3 6 0.1 .2
Oleic C18:1n9 14 6 1 14 6 1 13 6 1 14 6 1 .07
Eicosenoic C20:1n9 0.2 6 0.05 0.2 6 0.05 0.2 6 0.04 0.2 6 0.06 .03
Nervonic C24:1n9 0.4 6 0.2 0.4 6 0.2 0.3 6 0.1 0.4 6 0.2 .04
Mean 6 standard deviation presented.
aP value calculated from analysis of variance for continuous variables.
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found that the O3I increased in a dose-dependent manner.
Baseline O3I, older age, gender, and physical activity level
were also associated with a higher O3I. Interestingly, when
they adjusted per unit body weight (grams/kilograms), the
authors found that the dose of EPA and DHA was still a
powerful univariate predictor of O3I. They also observed
that subjects who weighed less and were receiving higher
doses experienced the greatest rise in their O3I. This
ﬁnding brings up an important consideration for achieving
an optimal O3I: that dosing recommendations for n-3PUFA should eventually be tailored to an individual’s de-
mographics and clinical history rather than being standard-
ized for the general population, as they are now.
Another strong predictor of O3I in this study was
having a smoking history, and it predicted a lower O3I.
Although smoking was highly prevalent in our cohort
(94% reported a history of smoking with average
pack-years of 47 6 35), signiﬁcant differences were noted
across the O3I tertiles: 100% of individuals with the lowest
O3I were smokers compared with 84% with the highest
O3I. A plausible reason for this correlation is that cigarette
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it is a chronic practice, and this may lead to destruction
of membrane PUFA.29 Supplementation with n-3 PUFA
may be protective because these fatty acids readily incorpo-
rate into cellular phospholipids, which leads to a relative
reduction of n-6 PUFA; a resulting increased n-3 to n-6
PUFA ratio has been shown to correlate with improved
endothelial function.30 Also, n-3 PUFA supplementation
could lead to recovery of endothelial synthesis of nitric
oxide and prostaglandin I2 as well as vascular smoothmuscle
cell sensitivity to nitric oxide. Siasos et al31 demonstrated that
addition of n-3 PUFA may attenuate the detrimental oxida-
tive effects that result from smoking. In their study of young
and healthy smokers, the authors found that endothelial
function signiﬁcantly improved after oral treatment with
2 g/day of n-3 PUFA for several months. Their results indi-
cate that supplementation could, in theory, lead to beneﬁts
in patients with PAD and should be examinedmore prospec-
tively. In another study that prospectively evaluated older
male smokers, current smoking status was associated with
development of claudication, whereas intake of n-6 PUFA
and certain antioxidants conferred a reduced risk of claudica-
tion onset.6 Whether smoking history is predictive of the
O3I is not yet conclusive because other studies have found
varying correlations.32,33 Therefore, this relation needs to
be explored further.
In our cohort of primarily white and male veterans with
PAD, older age predicted a higher O3I in univariate anal-
ysis and showed an even stronger correlation after adjust-
ment for n-3 PUFA supplementation and other potential
confounders. This association has been reported previously
and in several different populations.12,17,34,35 Because older
age is more associated with chronic conditions requiring
medication use, this may imply an increased likelihood of
taking supplements. Previous authors have reported a
biochemical basis35 for the higher O3I observed in older
age, noting that potential mechanismsmay include preferen-
tial incorporation of n-3 PUFA relative to other fatty acids36
and a declining turnover rate of membrane n-3 PUFA.12
Further research is required to better understand the
biochemical and physiologic mechanisms for the age-
related differences of the O3I.
Despite attempts at treatment with available medical
therapies, patients with PAD continue to have a higher
risk of cardiovascular events compared with patients with
CAD alone.2,37 Our ﬁndings are signiﬁcant for showing
that factors reported to correlate with the O3I in non-
PAD populations also apply to those with PAD. Conse-
quently, counseling of PAD patients about changes in
diet to include more naturally occurring n-3 PUFA or sup-
plementing with greater doses of n-3 PUFA may increase
their O3I and could potentially improve their symptoms
and prognosis. Additional prospective trials are warranted
to determine if dietary supplementation can improve
clinical outcomes in this population.
Limitations. This cross-sectional study was observa-
tional in nature and included a relatively small sample size.
We also lacked data on the exact amounts of prior EPA andDHA supplementation as well as ﬁsh consumption.
The patient population studied was not representative of
the broader PAD population as it included predominantly
white male veterans from SF VAMC. Gender could not
be controlled for because of the two female patients
included in the analysis. In addition, our study did not
include patients with asymptomatic or premature PAD or
any individuals with more advanced stages of the disease
(eg, those with renal or hepatic failure).
CONCLUSIONS
In a cohort of patients with PAD, the O3I was posi-
tively associated with a history of supplementation with
n-3 PUFA, older age, and higher BMI. A negative correla-
tion existed with smoking history. Additional large, pro-
spective studies are needed to determine if manipulation
of the O3I by dietary changes or ﬁsh oil supplementation
could improve symptoms, vascular function, or cardiovas-
cular risk in this population.
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